ASPIRA PATHLAB & DIAGNOSTICS | DR.AGAR.EYE | ASPIRA PATHLAB & DIAGNOSTICS / DR.AGAR.EYE |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -13.4 | 35.8 | - | View Chart |
P/BV | x | 2.6 | 14.7 | 17.4% | View Chart |
Dividend Yield | % | 0.0 | 0.1 | - |
ASPIRA PATHLAB & DIAGNOSTICS DR.AGAR.EYE |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASPIRA PATHLAB & DIAGNOSTICS Mar-23 |
DR.AGAR.EYE Mar-23 |
ASPIRA PATHLAB & DIAGNOSTICS / DR.AGAR.EYE |
5-Yr Chart Click to enlarge
|
||
High | Rs | 75 | 1,580 | 4.7% | |
Low | Rs | 26 | 545 | 4.7% | |
Sales per share (Unadj.) | Rs | 14.0 | 570.0 | 2.5% | |
Earnings per share (Unadj.) | Rs | -0.1 | 78.6 | -0.1% | |
Cash flow per share (Unadj.) | Rs | 1.5 | 121.5 | 1.2% | |
Dividends per share (Unadj.) | Rs | 0 | 3.00 | 0.0% | |
Avg Dividend yield | % | 0 | 0.3 | 0.0% | |
Book value per share (Unadj.) | Rs | 12.4 | 241.1 | 5.1% | |
Shares outstanding (eoy) | m | 10.29 | 4.70 | 218.9% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.6 | 1.9 | 192.2% | |
Avg P/E ratio | x | -583.7 | 13.5 | -4,315.1% | |
P/CF ratio (eoy) | x | 34.6 | 8.7 | 395.7% | |
Price / Book Value ratio | x | 4.1 | 4.4 | 92.2% | |
Dividend payout | % | 0 | 3.8 | -0.0% | |
Avg Mkt Cap | Rs m | 518 | 4,994 | 10.4% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 56 | 533 | 10.5% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 145 | 2,679 | 5.4% | |
Other income | Rs m | 3 | 21 | 15.7% | |
Total revenues | Rs m | 148 | 2,699 | 5.5% | |
Gross profit | Rs m | 16 | 756 | 2.1% | |
Depreciation | Rs m | 16 | 202 | 7.9% | |
Interest | Rs m | 4 | 80 | 5.2% | |
Profit before tax | Rs m | -1 | 494 | -0.2% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 0 | 125 | 0.0% | |
Profit after tax | Rs m | -1 | 369 | -0.2% | |
Gross profit margin | % | 11.0 | 28.2 | 39.1% | |
Effective tax rate | % | 0 | 25.3 | -0.0% | |
Net profit margin | % | -0.6 | 13.8 | -4.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 59 | 465 | 12.6% | |
Current liabilities | Rs m | 16 | 964 | 1.6% | |
Net working cap to sales | % | 29.5 | -18.6 | -158.7% | |
Current ratio | x | 3.7 | 0.5 | 765.3% | |
Inventory Days | Days | 88 | 71 | 122.9% | |
Debtors Days | Days | 590 | 1 | 42,859.4% | |
Net fixed assets | Rs m | 115 | 3,750 | 3.1% | |
Share capital | Rs m | 103 | 47 | 219.0% | |
"Free" reserves | Rs m | 25 | 1,086 | 2.3% | |
Net worth | Rs m | 128 | 1,133 | 11.2% | |
Long term debt | Rs m | 10 | 358 | 2.7% | |
Total assets | Rs m | 173 | 4,216 | 4.1% | |
Interest coverage | x | 0.8 | 7.1 | 11.0% | |
Debt to equity ratio | x | 0.1 | 0.3 | 23.9% | |
Sales to assets ratio | x | 0.8 | 0.6 | 131.2% | |
Return on assets | % | 1.9 | 10.7 | 17.8% | |
Return on equity | % | -0.7 | 32.6 | -2.1% | |
Return on capital | % | 2.4 | 38.5 | 6.2% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 0 | 0 | - | |
Fx outflow | Rs m | 0 | 9 | 0.0% | |
Net fx | Rs m | 0 | -9 | -0.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 0 | 696 | -0.0% | |
From Investments | Rs m | 2 | -706 | -0.2% | |
From Financial Activity | Rs m | -9 | 3 | -359.6% | |
Net Cashflow | Rs m | -8 | -7 | 107.9% |
Indian Promoters | % | 18.7 | 71.9 | 26.0% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 0.6 | - | |
FIIs | % | 0.0 | 0.6 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 81.3 | 28.1 | 289.3% | |
Shareholders | 1,512 | 3,572 | 42.3% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASPIRA PATHLAB & DIAGNOSTICS With: APOLLO HOSPITALS DR. LAL PATHLABS METROPOLIS HEALTHCARE NARAYANA HRUDAYALAYA KIMS
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | ASPIRA PATHLAB & DIAGNOSTICS | DR.AGAR.EYE | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -2.14% | -0.84% | -0.53% |
1-Month | -8.93% | 8.23% | -0.62% |
1-Year | -3.33% | 187.50% | 52.97% |
3-Year CAGR | 1.86% | 113.36% | 14.71% |
5-Year CAGR | -1.91% | 58.80% | 19.66% |
* Compound Annual Growth Rate
Here are more details on the ASPIRA PATHLAB & DIAGNOSTICS share price and the DR.AGAR.EYE share price.
Moving on to shareholding structures...
The promoters of ASPIRA PATHLAB & DIAGNOSTICS hold a 18.7% stake in the company. In case of DR.AGAR.EYE the stake stands at 71.9%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of ASPIRA PATHLAB & DIAGNOSTICS and the shareholding pattern of DR.AGAR.EYE.
Finally, a word on dividends...
In the most recent financial year, ASPIRA PATHLAB & DIAGNOSTICS paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
DR.AGAR.EYE paid Rs 3.0, and its dividend payout ratio stood at 3.8%.
You may visit here to review the dividend history of ASPIRA PATHLAB & DIAGNOSTICS , and the dividend history of DR.AGAR.EYE.
For a sector overview, read our pharmaceuticals sector report.
Asian stocks got off to a positive start on Monday ahead of the Federal Reserve's policy meeting later in the week.